Post New Job

GLP-1 receptor agonists: European drug regulator asks makers for evidence of self-harm

The European Medicines Agency (EMA) has asked some licence holders of GLP-1 receptor agonists for evidence into associations with suicidal ideation and self-harm as part of a review. These drugs include Ozempic (semaglutide), Saxenda (liraglutide), and Wegovy (semaglutide) and are used to treat type 2 diabetes and in weight management.

The review was triggered by the Icelandic Medicines Agency in July after reports of suicidal thoughts and self-injury in people using liraglutide and semaglutide. The authorities have so far retrieved and analysed about 150 reports of possible cases of self-injury and suicidal thoughts.

The EMA’s …

Source link

  • Share this post

Leave a Comment

 
Required 'Candidate' login to applying this job. Click here to logout And try again
 
 

Answers

 

Account Activation

Before you can login, you must activate your account with the code sent to your email address. If you did not receive this email, please check your junk/spam folder. Click here to resend the activation email. If you entered an incorrect email address, you will need to re-register with the correct email address.